Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept)

 April 15, 2026

Big Molecule Watch

On April 2, 2026, Regeneron Pharmaceuticals announced that the U.S.

RegulatoryOphthalmologyRead full story

Post navigation

Lilly to acquire CrossBridge Bio for up to $300m →
← Travere wins long-awaited approval for kidney disease drug

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com